Subscribe to Drug Discovery & Development Articles

The Lead

Developing Multi-Functional Anti-Inflammatory Drugs

July 24, 2014 | by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics | Comments

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...

View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Some 500 Genes Differ in Bipolar Patients’ Neurons

July 2, 2014 3:16 pm | by Cynthia Fox, Science Editor | Comments

Neurons of patients with bipolar disorder (BP) differ from the norm in a “striking” 500 or so genes, according to preliminary data generated using the Nobel-Prize-winning iPSC (induced pluripotent stem cell) approach, by Salk Institute neuroscientist Fred Gage. Read more...


Innovation Reins in Runaway Pharma Spending

July 1, 2014 1:21 pm | by Nancy Dreyfus, Contributing Science Writer | Comments

To combat the rising costs of bringing a new drug to market, pharmaceutical companies have taken a variety of innovative approaches, according to the U.K. Office of Health Economics, such as deciding earlier in the R&D process to discontinue drugs lacking strong market prospects and better controlling clinical costs. Read more...


Keeping the Lid on R&D Costs

June 23, 2014 11:14 am | by Nancy Dreyfus, Contributing Science Writer | Comments

In the past, pharmaceutical companies bolstered profits with billion-dollar blockbuster drugs that treated large populations for common conditions, but with patents running out, and development costs soaring, that business model may no longer be sustainable. Read more...


Neurogenic Drug Improves Depression in Small Trial

June 16, 2014 9:54 am | by Cynthia Fox, Science Editor | Comments

The first small molecule drug discovered with the aid of stem cells - NSI-189, a benzylpiperizine-aminiopyridine - has significantly affected major depressive disorder (MDD) in a small group of patients, Harvard neurologists report this week. Read more...


Preserving the Future of Drug Discovery

June 9, 2014 9:37 am | by Lori Ball, Chief Operating Officer, BioStorage Technologies | Comments

Biospecimens - and the genetic and genomic information derived from these materials - serve as the framework for the translational medicine research used to develop new drugs, novel biomarkers and personalized molecular diagnostics. Read more...     


Personalized Cancer Therapies Come of Age

June 3, 2014 8:44 am | by Sean Harper, M.D., Executive Vice President of Research and Development, Amgen | Comments

For many decades, scientific advances in cancer treatment were characterized by a slow, non-linear progress that resulted in treatments with a less than stellar ability to target cancer cells. Now, the advent of biomarker-driven drug development and the drive toward personalized medicine have provided a new approach to the treatment of advanced cancer. Read more...


Anti-Depressant Reduces Alzheimer’s Plaque Growth by 78%

May 15, 2014 1:32 pm | by Cynthia Fox, Science Editor | Comments

A common antidepressant - the selective serotonin reuptake inhibitor (SSRI) citalopram - can dramatically halt growth of Alzheimer’s plaque, report a team from Missouri and Pennsylvania Wednesday in Science Translational Medicine. Read more...


AbbVie Eyes Hepatitis C Cure with New Regimen

May 14, 2014 1:47 pm | by Christina Jakubowski, News Editor | Comments

AbbVie is tossing its metaphorical hat into the quickly growing and highly competitive hepatitis C treatment ring with an experimental, all-oral, interferon-free regimen – one that is boasting sustained viral response rates 12 weeks post treatment (SVR12 rates) that range from 90 to 100%. Read more...


Researchers Find Clue to Cancer Cell Autocannibalism

May 8, 2014 8:30 am | by Cynthia Fox, Science Editor | Comments

Autophagy, where cells "eat" parts of themselves in response to stress, may prompt cancer cells to revive and proliferate in response to chemotherapies— not die— according to a recent Cell Reports study by the University of Colorado Cancer Center. Read more...


Droplet Digital PCR Advances the Treatment of Cancer

May 6, 2014 9:49 am | by George Karlin-Neumann, Director of Scientific Affairs, Bio-Rad Digital Biology Center, Pleasanton, Calif. | Comments

One of the more exciting new technologies contributing to current advancements in cancer is droplet digital PCR (ddPCR), a method that is already being shown to track both favorable and unfavorable responses to therapy more rapidly than current imaging methods and to enable improved treatments. Read more...


Stem Cells That 'Hide' HIV May Bring New Therapies

April 30, 2014 9:22 am | by Cynthia Fox, Science Writer | Comments

The long life of a newly discovered stem cell in the blood may be responsible for HIV’s persistence, says new research, for it appears HIV hides, not just in memory T cells as thought—but in far longer-lived memory T stem cells. Read more... 


Faking Fluorescence

April 9, 2014 11:05 am | by Takeharu Nagai, Ph.D., Osaka University, Japan | Comments

The world’s brightest luminescent protein, a discovery dubbed the “Nano-lantern,” is lighting up the future of in vivo imaging– without the use of external light. This could benefit more advanced applications, such as high-throughput drug screening and single-cell tracking in live animals and plants.


Next-Gen Gene Synthesis Will Accelerate Biopharmaceutical Design and Development

March 4, 2014 3:56 pm | by Kevin Munnelly, CEO, Gen9 | Comments

With the biopharmaceutical market valued at $70 billion and counting, scientists need every improvement they can get to design and develop these drugs faster and more accurately. A novel technology that will bring synthetic biology to industrial scale promises to dramatically enhance the development pipeline.


Druggable Link Found Between Inflammation, Breast Cancer Stem Cells

March 4, 2014 3:47 pm | by Cynthia Fox, Science Editor | Comments

In the deadliest breast cancers, a protein driving inflammation fails to shut down, prompting increases in cancer stem cells, according to new research. This new link gives researchers a new potential target for treating triple-negative breast cancer (TNBC). The research indicates that drugs that should potentially be tried on breast cancer patients in clinical trial include over-the-counter anti-inflammatories like aspirin and Naproxen.


New Therapy Targets Prospective Older Bone Marrow Transplant Patients

February 20, 2014 9:45 am | by Kaushik J. Dave, Ph.D. | Comments

Bone marrow transplants are the only potential cure for many blood cancers in older patients, but many in this group are ruled ineligible because the procedure is often deemed too harsh for older people. Since more than half of AML patients are over 65 years old, new tactics to prepare these patients for hematopoietic stem cell transplantation are needed.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.